Claire Mazumdar, Chief Executive Officer at Bicara Therapeutics Inc. (BCAX), sold 30,000 shares at $18.84 ($565K) on 2026-03-18, disclosed to the SEC on 2026-03-20.
Scheduled sale ($565k) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $18.84 | 6,499 | $122K | 21.7% |
| 2 | $18.84 | 6,499 | $122K | 21.7% |
| 3 | $18.78 | 6,905 | $130K | 23.0% |
| 4 | $18.78 | 6,905 | $130K | 23.0% |
| 5 | $18.95 | 1,596 | $30K | 5.4% |
| 6 | $18.95 | 1,596 |
| $30K |
| 5.4% |
| Total | $18.82 avg | 30,000 | $565K | 100% |
| Filing → |
| BCAX | SELL | 2026-05-20 | $301K | — | Filing → |
| BCAX | SELL | 2026-04-20 | $354K | — | Filing → |
| BCAX | SELL | 2026-03-11 | $1.4M | — | Filing → |